Drug Trial Radar · NCT03270059
Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
41
Actual
Start
Oct 6, 2017
Primary completion
Dec 15, 2027
Study completion Dec 15, 2028
Sponsor
- Lead sponsor
- OHSU Knight Cancer InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Celgene Corporation; Oregon Health and Science University
- First posted
- Sep 1, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 10 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies how well gadolinium and ferumoxytol magnetic resonance imaging (MRI) work in diagnosing patients with abnormalities in the central nervous system. Diagnostic procedures, such as gadolinium and ferumoxytol MRI, may help find and diagnose abnormalities in the central nervous system.
Conditions
- Central Nervous System Neoplasm
- Cranial Nerve Disorder
- Metastatic Malignant Neoplasm in the Brain
Interventions
FerumoxytolDrug
Given IV
GadoliniumDrug
Given IV
Magnetic Resonance ImagingProcedure
Undergo MRI
Primary outcomes
What the sponsor says the trial is designed to measure.
- Visualization of normal vasculatureTime frame: Up to 5 years
- Visualization of abnormal vasculatureTime frame: Up to 5 years
- Visualization of normal anatomical structuresTime frame: Up to 5 years
- Identification of the lesion corresponding areas on cerebral blood volume (CBV) mapsTime frame: Up to 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
OHSU Knight Cancer Institute
Portland, Oregon
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.